François Ghiringhelli Unité Inserm 866 « Lipides, nutrition et cancer » Centre Georges François Leclerc Tel. 03.80.39.33.53 email@example.com
Priscille Rivière firstname.lastname@example.org
An Inserm team in Dijon directed by François Ghiringhelli (Inserm unit 866 ‘Lipids, nutrition and cancer’) is to publish an article this week in the Nature Medicine review. The article suggests that two chemotherapy drugs frequently used to treat digestive and breast cancers may encourage the development of tumours by modulating the anti-tumoural immune response. These results reveal how the immune system can then limit the effectiveness of some cancer chemotherapies. The researchers now intend to block the molecules responsible for negative immune system activation to increase the efficiency of chemotherapy. A clinical trial to test this hypothesis should begin very soon.
Chemotherapy is one of the most frequently used treatments to eliminate cancerous cells. These drugs kill all cells that are multiplying, or block their proliferation (for example, cells responsible for hair growth, explaining the hair loss of treated patients). In addition to their direct toxic effects, the chemotherapeutic agents also seem to act on the immune system and could make it possible for the body to trigger a direct antitumor immune response in a second phase.
However, this last point is still the subject of hot debate, since some studies suggest, conversely, that chemotherapy eliminates all immune defences.
The Inserm team directed by Professor François Ghiringhelli (Inserm unit 866 “Lipids, nutrition and cancer”) from the Georges François Leclerc Cancer Research Centre in Dijon observed that two chemotherapeutic agents, 5-fluorouracile and gemcitabine, used to treat colon, breast and pancreas cancers activate a protein complex “inflammasome NLRP3” within some cells in the immune system.
To be more specific, this activation leads to releasing proinflammatory cytokine (interleukin IL-1beta) through these cells. This cytokine “distorts” the immune response related to lymphocytes T and causes the production of another cytokine (cytokine IL-17), which has protumoral properties by encouraging tumour angiogenesis, i.e. vascular irrigation of tumours.
The first was to test the two drugs on inflammasome NLRP3- or cytokine IL-17-deficient mice. In these cases, the researchers showed that antitumor activity was not only present, but it actually increased, demonstrating that these two elements (NLRP3 and IL-17) slow down the chemotherapy action.
The second strategy was to treat the mice using an IL-1beta inhibitor. Here again, the effectiveness of chemotherapy was again increased.
These results suggest that targeting the inflammasome and IL-1beta channels, combined with the use of these two chemotherapy agents, can improve the effectiveness of the latter. These tumour cells are eliminated and, in parallel, the damaging immune responses are deleted.
A therapeutic trial combining 5-fluorouracil and IL-1 beta is currently being prepared and should begin soon at the Georges François Leclerc Cancer Research in Dijon.
Publiée dans le Journal of Clinical Oncology, une nouvelle analyse de la cohorte CANTO (CANcer TOxicities) identifie les déterminants de la reprise de l’activité professionnelle après un cancer du sein. ...
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth Mélanie Bruchard1,2,8, Grégoire Mignot1,2,8, Valentin Derangère1,2, Fanny Chalmin1,2, Angélique Chevriaux1–3, Frédérique Végran1,2, Wilfrid Boireau4, Benoit Simon4, Bernhard Ryffel5, Jean Louis Connat6, Jean Kanellopoulos7, François Martin1,2, Cédric Rébé1–3, Lionel Apetoh1–3,8 & François Ghiringhelli1–3,8 1-Institut National de la Santé et de la Recherche Médicale (INSERM) U866, Dijon, France. 2-Faculté de Médecine et pharmacie, Université de Bourgogne, Dijon, France. 3-Centre Georges François Leclerc, Dijon, France. 4-Franche-Comté Electronique, Mécanique, Thermique et Optique–Sciences et Technologies (FEMTO-ST) Institute, Université de Franche Comté, Besançon, France. 5-Laboratory of MolecularImmunology and Embryology, Centre National de la Recherche Scientifique (CNRS) Unités Mixtes de Recherche (UMR) 6218, Orléans, France. 6-INSERM U866, Laboratoire de Physiopathologie et Pharmacologie Cardiovasculaires Expérimentales, Institut Fédérative de Recherche (IFR) Santé–Sciences et Techniques de l′Information et de la Communication (STIC), Faculté de Médecine, Université de Bourgogne, Dijon, France. 7-UMR 8619, Université Paris Sud-Paris 11, Orsay Cedex, France. 8These authors contributed equally to this work. Nature medicine décembre 2012, http://dx.doi.org/10.1038/nm.2999